ATI commences European trial of neurostimulation program for migraine Autonomic Technologies.

ATI commences European trial of neurostimulation program for migraine Autonomic Technologies, Inc. , the developer of a novel miniaturized implantable stimulator for serious head aches, today announced initiation of a report in Europe to judge the protection and efficacy of the company’s investigational neurostimulation system for the treating high frequency, high disability migraine. The multi-center, randomized Pathway M-1 study will enroll 30 individuals initially at leading headache centers in Denmark, Belgium, Spain, France and Germany. Migraine is the most common disabling headache, influencing 11 percent of the population in Western European countries and the United States.To initiate many important functions, bacteria occasionally depend entirely upon ancient forms of RNA, once viewed just as the chemical substance intermediary between DNA’s instructions and the creation of proteins, stated Ronald Breaker, the Henry Ford II Professor of Molecular, Cellular and Developmental Biology at Yale and senior author of the study. Proteins carry out almost all of life’s cellular functions today, but many scientists like Breaker believe this is not necessarily the case and also have found many good examples where RNA plays a amazingly large part in regulating cellular activity. The Science research illustrates that – in bacteria, at least – proteins are not necessary to spur a bunch of fundamental cellular adjustments always, an activity Breaker believes was common on Earth some 4 billion years back, prior to DNA existed.